La presente informativa è resa, anche ai sensi dell’art. 13 del D. Lgs. 196/2003 “Codice in materia di protezione dei dati personali” (“Codice Privacy”) 
e degli artt. 13 e 14 del Regolamento (UE) 2016/679 (“GDPR”), a coloro che si collegano alla presente edizione online del giornale Tribuna Economica di proprietà di AFC Editore Soc. Coop. 

Leggi di più


Mauna Kea Technologies (Euronext: MKEA) inventor of Cellvizio, the multidisciplinary probe-based and needle-based confocal laser endomicroscopy (pCLE/nCLE) platform, and the European Investment Bank (EIB),

which is the Bank of the European Union (EU), announce the signing of a 22.5 million euros loan agreement, supported by the European Strategic Investment Fund (EFSI) or "Juncker Plan".

This loan will enable Mauna Kea Technologies to intensify its market development efforts, to further invest in its research, development and innovation activities and, if needed, to increase its production capacity based on strong demand trends over the next several years. The first €11.5 million tranche is to be released in the coming weeks, while the subsequent €6 and €5 million tranches will be released in the coming years subject to the achievement of certain milestones including the Company's commercial progress and future equity capital financing activities. The loan agreement is secured and is supplemented by an agreement to issue share warrants to the EIB for the first two tranches of the financing, covering 1,450,000 and 300,000 shares respectively (5.75% and 1.2% of the current share capital).

The aim of this type of financing, granted by the EIB with the European guarantee within the framework of the Juncker plan, is to support research and innovation projects developed by companies with substantial growth potential. Mauna Kea Technologies meets these criteria as its technologies have the potential to impact the lives of hundreds of thousands of patients in Europe.

The agreement was signed by Ambroise Fayolle, EIB Vice-President, and Sacha Loiseau, Chairman and Founder of Mauna Kea Technologies, during a visit to the company's headquarters in Paris.

This project is fully in line with the mandate given to the EIB by its shareholders - the EU Member States - to support innovation throughout Europe”, stresses EIB Vice-President Ambroise Fayolle. “The Medtech company Mauna Kea Technologies, with its unique confocal laser endomicroscopy platform, has the potential to become a world leader in its field and represents the very example of companies essential for the future of the European economy, combining a high level of research in innovation and the employment of highly skilled workers.”